PLYX

Polaryx Therapeutics, Inc.

Price Chart

Latest Quote

$2.31

-0.10 (-4.15%)

Current Price

Previous Close	$2.41
Open	$2.40
Day High	$2.47
Day Low	$2.27
Volume	44,254

Fetched: 2026-07-17T08:44:14

Stock Information

Shares Outstanding	49.85M
Cash Equivalents	$3.08M
Net Income	$-6.48M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$113.65M
EPS (TTM)	$-0.13
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$104.86M
Income	$-6.48M
Book/sh	$0.05
Cash/sh	$0.06
Employees	2

Financial Ratios

Quick Ratio	3.04
Current Ratio	3.45

Returns & Margins

ROA	-74.42%
ROE	-192.17%

Ownership

Insider Ownership	69.34%
Institutional Ownership	4.55%
Insider & Institutional transactions data not available

Valuation Ratios

P/B

43.02

Analyst Data

Recommendation	strong_buy
Target Price	$8.50

Technical Indicators

SMA20	$2.44
SMA50	$2.72
RSI	46.15
ATR	0.2464

Shares Float	4.28M
Short Float	1.89%
Short Ratio	2.48
Rel Volume	0.57

Performance History

Week	-2.15%
Month	-0.44%
Quarter	-64.32%
YTD	-93.49%
10 Years	-93.49%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-07-17	$2.28	58,000
2026-07-16	$2.31	44,300
2026-07-15	$2.41	80,800
2026-07-14	$2.26	67,200
2026-07-13	$2.20	99,700
2026-07-10	$2.33	130,500
2026-07-09	$2.43	109,000
2026-07-08	$2.55	61,400
2026-07-07	$2.53	88,100
2026-07-06	$2.65	64,300
2026-07-02	$2.81	236,200
2026-07-01	$2.58	76,500
2026-06-30	$2.66	176,400
2026-06-29	$2.53	336,600
2026-06-26	$2.40	100,100
2026-06-25	$2.31	32,900
2026-06-24	$2.40	44,300
2026-06-23	$2.41	58,900
2026-06-22	$2.41	62,100
2026-06-18	$2.32	105,800

About Polaryx Therapeutics, Inc.

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.

📰 Latest News

Polaryx to present late-breaker data related to Soteria ahead of trial

TipRanks • 2026-02-04T13:40:26Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31
Revenue
Total Revenue	$0	$0	$0
Operating Revenue	$0	$0	$0
Expenses
Total Expenses	$7,821,000	$4,352,000	$3,781,000
Other Income Expense	$-1,164,000	$-26,004,000	$2,000
Operating Expense	$7,821,000	$4,352,000	$3,781,000
General And Administrative Expense	$1,555,000	$1,541,000	$1,010,000
Other Non Operating Income Expenses	-	$-26,004,000	$2,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-8,985,000	$-30,356,000	$-3,779,000
Normalized Income	$-7,821,000	$-30,356,000	$-3,779,000
Net Income From Continuing And Discontinued Operation	$-8,985,000	$-30,356,000	$-3,779,000
Total Operating Income As Reported	$-7,821,000	$-4,352,000	$-3,781,000
Net Income Common Stockholders	$-8,985,000	$-30,356,000	$-3,779,000
Net Income	$-8,985,000	$-30,356,000	$-3,779,000
Net Income Including Noncontrolling Interests	$-8,985,000	$-30,356,000	$-3,779,000
Net Income Continuous Operations	$-8,985,000	$-30,356,000	$-3,779,000
Pretax Income	$-8,985,000	$-30,356,000	$-3,779,000
Special Income Charges	$-1,164,000	$0	-
Operating Income	$-7,821,000	$-4,352,000	$-3,781,000
Per Share
Diluted EPS	$-0.19	$-0.64	$-0.08
Basic EPS	$-0.19	$-0.64	$-0.08
Other
Tax Effect Of Unusual Items	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-6,657,000	$-4,352,000	$-3,781,000
Total Unusual Items	$-1,164,000	$0	-
Total Unusual Items Excluding Goodwill	$-1,164,000	$0	-
EBITDA (Bullshit earnings)	$-7,821,000	$-4,352,000	$-3,781,000
EBIT	$-7,821,000	$-4,352,000	$-3,781,000
Diluted Average Shares	$47,343,297	$47,343,297	$47,343,297
Basic Average Shares	$47,343,297	$47,343,297	$47,343,297
Diluted NI Availto Com Stockholders	$-8,985,000	$-30,356,000	$-3,779,000
Other Special Charges	$1,164,000	-	-
Research And Development	$6,266,000	$2,811,000	$2,771,000
Selling General And Administration	$1,555,000	$1,541,000	$1,010,000
Other Gand A	$1,555,000	$1,541,000	$1,010,000

Fetched: 2026-07-08

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31
Assets
Net Tangible Assets	$4,565,000	$4,712,000	$1,277,000
Total Assets	$5,170,000	$5,001,000	$2,315,000
Total Non Current Assets	$0	$0	$0
Current Assets	$5,170,000	$5,001,000	$2,315,000
Other Current Assets	$27,000	-	-
Prepaid Assets	$0	$380,000	$2,313,000
Cash Cash Equivalents And Short Term Investments	$5,143,000	$4,621,000	$2,000
Cash And Cash Equivalents	$5,143,000	$4,621,000	$2,000
Debt
Net Debt	-	-	$126,000
Total Debt	-	-	$128,000
Current Debt And Capital Lease Obligation	-	-	$128,000
Current Debt	-	-	$128,000
Other Current Borrowings	-	-	$128,000
Liabilities
Total Liabilities Net Minority Interest	$605,000	$289,000	$1,038,000
Total Non Current Liabilities Net Minority Interest	$0	$0	$0
Current Liabilities	$605,000	$289,000	$1,038,000
Payables And Accrued Expenses	$584,000	$288,000	$909,000
Payables	$561,000	$202,000	$823,000
Accounts Payable	$470,000	$72,000	$473,000
Equity
Common Stock Equity	$4,565,000	$4,712,000	$1,277,000
Total Equity Gross Minority Interest	$4,565,000	$4,712,000	$1,277,000
Stockholders Equity	$4,565,000	$4,712,000	$1,277,000
Retained Earnings	$-99,635,000	$-90,650,000	$-60,294,000
Other
Ordinary Shares Number	$47,343,297	$47,343,297	$47,343,297
Share Issued	$47,343,297	$47,343,297	$47,343,297
Tangible Book Value	$4,565,000	$4,712,000	$1,277,000
Invested Capital	$4,565,000	$4,712,000	$1,405,000
Working Capital	$4,565,000	$4,712,000	$1,277,000
Total Capitalization	$4,565,000	$4,712,000	$1,277,000
Additional Paid In Capital	$104,195,000	$95,358,000	$61,570,000
Capital Stock	$5,000	$4,000	$1,000
Common Stock	$5,000	$4,000	$1,000
Preferred Stock	$0	$0	$0
Pensionand Other Post Retirement Benefit Plans Current	$21,000	$1,000	$1,000
Current Accrued Expenses	$23,000	$86,000	$86,000
Dueto Related Parties Current	$91,000	$130,000	$350,000

Fetched: 2026-07-08

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31
Free Cash Flow
Free Cash Flow	$-3,944,000	$-2,573,000	$-173,000
Operating Activities
Operating Cash Flow	$-3,944,000	$-2,573,000	$-173,000
Cash Flow From Continuing Operating Activities	$-3,944,000	$-2,573,000	$-173,000
Financing Activities
Issuance Of Capital Stock	$4,493,000	$7,320,000	$0
Financing Cash Flow	$4,466,000	$7,192,000	$128,000
Cash Flow From Continuing Financing Activities	$4,466,000	$7,192,000	$128,000
Net Other Financing Charges	$-27,000	-	-
Net Common Stock Issuance	$4,493,000	$7,320,000	$0
Common Stock Issuance	$4,493,000	$7,320,000	$0
Other
Repayment Of Debt	$0	$-193,000	$0
Issuance Of Debt	$0	$65,000	$128,000
End Cash Position	$5,143,000	$4,621,000	$2,000
Beginning Cash Position	$4,621,000	$2,000	$47,000
Changes In Cash	$522,000	$4,619,000	$-45,000
Net Issuance Payments Of Debt	$0	$-128,000	$128,000
Net Short Term Debt Issuance	$0	$-128,000	$128,000
Short Term Debt Payments	$0	$-193,000	$0
Short Term Debt Issuance	$0	$65,000	$128,000
Change In Working Capital	$316,000	$-621,000	$369,000
Change In Payables And Accrued Expense	$316,000	$-621,000	$294,000
Change In Accrued Expense	$-43,000	$0	$-4,000
Change In Payable	$359,000	$-621,000	$298,000
Change In Account Payable	$398,000	$-401,000	$-52,000
Stock Based Compensation	$4,725,000	$2,400,000	$3,237,000
Net Income From Continuing Operations	$-8,985,000	$-30,356,000	$-3,779,000
Change In Prepaid Assets	-	$0	$75,000
Other Non Cash Items	-	$26,004,000	-

Fetched: 2026-07-08